Literature DB >> 17932694

One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases.

E Descloux1, T Perpoint, T Ferry, G Lina, M Bes, F Vandenesch, I Mohammedi, J Etienne.   

Abstract

Staphylococcus aureus superantigenic toxins are responsible for menstrual and non-menstrual toxic shock syndrome (TSS). We compared the clinical and biological characteristics of 21 cases of menstrual TSS (MTSS) with 34 cases of non-menstrual TSS (NMTSS) diagnosed in France from December 2003 to June 2006. All 55 S. aureus isolates had been spontaneously referred to the French National Staphylococcal Reference Center, where they were screened for superantigenic toxin gene sequences. Most of the patients had previously been in good health. The most striking differences between MTSS and NMTSS were the higher frequency in NMTSS of neurological disorders (p=0.028), of S. aureus isolation by blood culture (50% versus 0% in MTSS), and the higher mortality rate in NMTSS (22% versus 0% in MTSS). The tst and sea genes were less frequent in isolates causing NMTSS than in those causing MTSS (p<0.001 and 0.051, respectively). Higher mortality was significantly associated with the presence of the sed gene (p=0.041), but when considering NMTSS survivors and non-survivors, no clinical or bacteriological factors predictive of vital outcome were identified. Specific antitoxinic therapy was rarely prescribed, and never in fatal cases. Higher mortality was observed in NMTSS than in MTSS, and no definite factors could explain the higher severity of NMTSS. NMTSS would require more aggressive therapy, comprising systematic rapid wound debridement, antistaphylococcal agents, including an antitoxin antibiotics, and intravenous immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17932694     DOI: 10.1007/s10096-007-0405-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

Review 1.  Toxic shock syndrome and bacterial superantigens: an update.

Authors:  J K McCormick; J M Yarwood; P M Schlievert
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

2.  Global repression of exotoxin synthesis by staphylococcal superantigens.

Authors:  Nikola Vojtov; Hope F Ross; Richard P Novick
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

3.  Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period.

Authors:  Patrick M Schlievert; Timothy J Tripp; Marnie L Peterson
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

4.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

5.  Comparative inflammatory properties of staphylococcal superantigenic enterotoxins SEA and SEG: implications for septic shock.

Authors:  Olivier Dauwalder; Damien Thomas; Tristan Ferry; Anne-Lise Debard; Cédric Badiou; François Vandenesch; Jerome Etienne; Gerard Lina; Guillaume Monneret
Journal:  J Leukoc Biol       Date:  2006-08-02       Impact factor: 4.962

6.  Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses.

Authors:  K C Kain; M Schulzer; A W Chow
Journal:  Clin Infect Dis       Date:  1993-01       Impact factor: 9.079

7.  Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro.

Authors:  Valérie Gauduchon; Gregoire Cozon; François Vandenesch; Anne-Laure Genestier; Nathalie Eyssade; Simone Peyrol; Jerome Etienne; Gerard Lina
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

8.  Effect of antibiotics on toxin production and viability of Clostridium perfringens.

Authors:  D L Stevens; K A Maier; J E Mitten
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin.

Authors:  C G Gemmell; P K Peterson; D Schmeling; Y Kim; J Mathews; L Wannamaker; P G Quie
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

10.  Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo.

Authors:  P F Bonventre; M R Thompson; L E Adinolfi; Z A Gillis; J Parsonnet
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

View more
  20 in total

1.  Prevalence of toxin genes in consecutive clinical isolates of Staphylococcus aureus and clinical impact.

Authors:  T-X Nhan; R Leclercq; V Cattoir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-12       Impact factor: 3.267

2.  Understanding toxic shock syndrome.

Authors:  Jason P Burnham; Marin H Kollef
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

3.  Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology.

Authors:  Peter A Szabo; Ankur Goswami; Delfina M Mazzuca; Kyoungok Kim; David B O'Gorman; David A Hess; Ian D Welch; Howard A Young; Bhagirath Singh; John K McCormick; S M Mansour Haeryfar
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

4.  Vaginal Tampon Colonization by Staphylococcus aureus in Healthy Women.

Authors:  Myriam Chiaruzzi; Alexia Barbry; Anaëlle Muggeo; Anne Tristan; Isaline Jacquemond; Cedric Badiou; Laurence Cluzeau; Sabine Bourdeau; Thibaut Durand; Astrid Engelmann; Dorian Bosquet; Michèle Bes; Claire Prigent-Combaret; Jean Thioulouse; Daniel Muller; Gérard Lina
Journal:  Appl Environ Microbiol       Date:  2020-09-01       Impact factor: 4.792

5.  New insights into the prevention of staphylococcal infections and toxic shock syndrome.

Authors:  Ying-Chi Lin; Marnie L Peterson
Journal:  Expert Rev Clin Pharmacol       Date:  2010-11-01       Impact factor: 5.045

6.  Toxin profiling of Staphylococcus aureus strains involved in varicella superinfection.

Authors:  Olivia Raulin; Géraldine Durand; Yves Gillet; Michèle Bes; Gerard Lina; François Vandenesch; Daniel Floret; Jerome Etienne; Frédéric Laurent
Journal:  J Clin Microbiol       Date:  2010-03-19       Impact factor: 5.948

Review 7.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

8.  Persistence survey of toxic shock syndrome toxin-1 producing Staphylococcus aureus and serum antibodies to this superantigen in five groups of menstruating women.

Authors:  Jeffrey Parsonnet; Melanie A Hansmann; Jon L Seymour; Mary L Delaney; Andrea M Dubois; Paul A Modern; Michaelle B Jones; John E Wild; Andrew B Onderdonk
Journal:  BMC Infect Dis       Date:  2010-08-23       Impact factor: 3.090

9.  Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.

Authors:  Eileen A Larkin; Bradley G Stiles; Robert G Ulrich
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

10.  CcpA mediates the catabolite repression of tst in Staphylococcus aureus.

Authors:  Kati Seidl; Markus Bischoff; Brigitte Berger-Bächi
Journal:  Infect Immun       Date:  2008-08-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.